Clinical Trials Browser

Interventional × gedatolisib × 90 days × Clear all

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant